Prospective,Randomized Trial Comparing Effect of Oral Versus Intravenous Pantoprazole on Rebleeding After Nonvariceal Upper Gastrointestinal Bleeding: A Pilot Study

Proton pump inhibitors (PPIs) reduce the rate of rebleeding in patients with nonvariceal upper GI bleed (NVGIB). Oral (PO) and intravenous (IV) pantoprazole are equipotent in raising gastric pH. We conducted a pilot study comparing the efficacy of PO vs. IV pantoprazole for reducing rebleeding after NVGIB. Patients with NVGIB were randomized to receive PO (80 mg BID for 3 days) or IV (80-mg IV bolus and 8 mg/hr infusion for 3 days) pantoprazole followed by pantoprazole, 40 mg PO BID, for 30 days. All patients underwent endoscopy within 24 hr and endotherapy was applied where necessary. Twelve patients randomized to the PO and 13 to the IV pantoprazole group were comparable in age, hematocrit, Rockall scores, ulcer characteristics, and endoscopic interventions. Two patients in the IV arm rebled and another in the IV arm developed reversible renal failure. No patient in the PO arm rebled, had organ failure, or had to be changed to IV pantoprazole. We conclude that in this pilot study, the effect of PO pantoprazole on 30-day rebleeding rate in patients with NVGIB was similar to that of IV pantoprazole.     

泮托拉唑治疗上消化道大出血疗效观察

目的：研究泮托拉唑治疗上消化道大出血的疗效。方法：将胃镜证实的非静脉曲张性非癌性上消化道大出血随机分成泮托拉唑组(A组)和西咪替丁组(B组)，其中A组46例，用泮托拉唑40mg静滴每12小时一次；B组47例，用西咪替丁200mg静滴每6小时1次。治疗期间注意监测血压、出血情况。结果：泮托拉唑组止血有效率为100％，显著高于西咪替丁组的70．21％。结论 泮托拉唑对非静脉曲张性非癌性上消化道大出血具有高效、迅速的作用。     

泮托拉唑治疗胃溃疡的疗效观察

目的观察泮托拉唑治疗胃溃疡的临床疗效。方法采用随机抽样，配对分组法将128例胃溃疡患者分为泮托拉唑组和雷尼替丁对照组。结果泮托拉唑对胃溃疡的8wk治愈率为92．19％，明显高于雷尼替丁组的68．75％，p〈0．01；（x^2=11．184）；且副作用少，总有效率分别为96．9%（62/64）和87．5（56／64），p〈0．05（x^2=3．905）。结论泮托拉唑治疗胃溃疡疗效显著。     

泮托拉唑钠与奥美拉唑钠在氯化钠注射液中的稳定性考察

目的:考察注射用泮托拉唑钠和注射用奥美拉唑钠与氯化钠注射液配伍稳定性。方法:用HPLC法考察配伍前后泮托拉唑钠与奥美拉唑钠的含量变化,并观察配伍液的外观及pH变化。结果:注射用泮托拉唑钠和注射用奥美拉唑钠与0.9%氯化钠注射液配伍后8 h内含量、pH及溶液外观均无明显变化。结论:注射用泮托拉唑钠和注射用奥美拉唑钠与氯化钠注射液配伍后在8 h内均稳定。     

潘托拉唑三联疗法与奥美拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡

目的：研究潘托拉唑治疗消化性溃疡及根除幽门螺杆菌（HP）的疗效和安全性。方法：将经过胃镜和病理学检查证实了的消化性溃疡患者随机分成潘托拉唑组（治疗组）和奥美拉唑组（对照组）。其中治疗组60例,应用潘托拉唑、羟氨苄青霉素和甲硝唑治疗;对照组57例,应用奥美 拉唑、羟氨苄青霉素和甲硝唑治疗。停药后均复查胃镜观察溃疡愈合情况以及HP根除情况。结果：两组胃溃疡的愈合率分别为92．3％和95．4％,HP根除率分别为92．3％和90．9％;十二指肠溃疡的愈合率分别为97．1％和94．3％,HP根除率分别为91．2％和94．3％,两组比较差异无显著性（P＞0．01）,各项症状的改善情况两组相似（P＞0．1）。治疗期间两组均有良好的耐受性。结论：潘托拉唑对消化性溃疡有很高的治愈率,以它为主的三联疗法可达到很高的HP根除率,对消化性溃疡的疗效与奥美拉唑相当,不良反应极少,患者耐受性,依从性好,是一种有广泛应用前景的新型质子泵抑制剂。     

国产潘托拉唑、克拉霉素治疗十二指肠溃疡合并幽门螺杆菌的临床研究

目的 :比较国产潘托拉唑与进口潘托拉唑对十二指肠球部溃疡的疗效 ;国产潘托拉唑、克拉霉素加羟氨苄青霉素三联抗幽门螺杆菌 (HP)方案对十二指肠球部溃疡合并HP感染的疗效。方法 :112例患者进入试验 ,可评价病例10 5例 ,试验包括两部分 :单用药部分 ( 4 5例 )随机分组 ,分别使用国产潘托拉唑和进口潘托拉唑 40mg ,每日 1次 ,用药 2周 ,比较溃疡愈合率 ;三联用药部分均为十二指肠球部溃疡合并HP感染者 ,随机分组 ,分别使用国产潘托拉唑和克拉霉素加羟氨苄青霉素与进口潘托拉唑和进口克拉霉素加羟氨苄青霉素。潘托拉唑疗程 2周 ,抗生素疗程 1周 ,比较HP根除率及用药期间的不良事件。结果 :国产和进口潘托拉唑治疗十二指肠球部溃疡 2周愈合率分别为 84 0 %和 80 0 % (P>0 0 5 ) ,3日疼痛缓解率分别为 70 2 %和 6 6 7% ,平均疼痛缓解时间分别为 4 2 1± 2 8天和 3 93± 1 8天 ;国产三联和进口三联HP根除率分别为 73 3 %和 83 3 % (P >0 0 5 ) ;国产药组与进口药组不良事件发生率分别为 3 4 0 %和3 2 0 % ,无显著性差异。结论 :国产潘托拉唑和克拉霉素在治疗十二指肠球部溃疡合并HP感染方面与进口同类产品相比疗效相当、同样安全而且价格较低 ,适合国内应用。     

泮托拉唑治疗消化性溃疡50例

目的：评价泮托拉唑对消化性溃疡的疗效。方法：93例经内镜证实的活动性消化性溃疡患者随机分为A,B两组,A组给予泮托拉唑40mg,每晨1次口服;B组给予雷尼替丁300mg,每晚睡前口服。两组疗程均为4周,结果：（1）A组平均上腹痛缓解天数为4．4d,溃疡愈合率96．0％,B组平均上腹痛缓解天数7．6d,溃疡愈合率69．8％,两组比较,前者上腹痛缓解天数显著少于后者（P＜0．05）,而溃疡愈合率显著高于后者（P＜0．01）。（2）在A组和B组中,十二指肠溃疡愈合率分别为96．9％和71．4％,胃溃疡愈合率分别为94．4％和66．7％,两组相比,差异均有显著性统计学意义（P＜0．01及P＜0．05）,结论：泮托拉唑是治疗消化性溃疡较为的药物,疗效明显优于雷尼替丁。     

静脉滴注潘妥拉唑对健康成人24小时胃内pH变化的影响

目的探讨质子泵阻滞剂潘妥拉唑对健康成人24h胃内pH变化的影响.方法利用DigitrapperMKⅢ动态pH监测仪观察10名健康志愿者24h胃内pH变化节律,1周后,分别于晨8时静脉滴注潘妥拉唑80mg,连续2d,并于第2天给药后立即进行24h胃内pH监测.结果健康成人24h胃内pH平均值为2.21±0.86,pH＞4总时间百分比为(15.75±13.60)%,24h胃内pH变化曲线下面积为1.90×105±0.80×105.静脉滴注潘妥拉唑后,24h胃内pH平均值、pH＞4总时间百分比、24h胃内pH变化曲线下面积分别升至7.18±1.06、(93.41±8.43)%及6.20×105±0.90×105(P＜0.01).结论正常人24h胃内pH变化节律证实,潘妥拉唑有较强的抑制胃酸分泌作用.     

Asthma and gastroesophageal reflux disease： Effect of long-term pantoprazole therapy

AIM: To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms. METHODS: Seven of thirty-four asthmatic patients without GERD served as the non-GERD control group. Twenty-seven of thirty-four asthmatic patients had GERD (7/27 also had erosive esophagitis, sixteen of them presented GERD symptoms. An upper gastrointestinal endoscopy was performed in all the subjects to obtain five biopsy specimens from the lower 5 cm of the esophagus. Patients were considered to have GERD when they had a dilation of intercellular space (DIS)>0.74 urn at transmission electron microscopy. Patients with GERD were treated with pantoprazole, 80 mg/day. Forced expiratory volume in one second (FEV1) was performed at entry and after 6 mo of treatment. Asthmatic symptoms were recorded. The required frequency of inhaling rapid acting β2-agonists was self-recorded in the patients' diaries. RESULTS: Seven symptomatic patients presented erosive esophagitis. Among the 18 asymptomatic patients, 11 presented DIS, while all symptomatic patients showed ultrastructural esophageal damage. Seven asymptomatic patients did not present DIS. At entry the mean of FEV1 was 1.91 L in symptomatic GERD patients and 1.88 L in asymptomatic GERD patients. After the treatment, 25 patients had a complete recovery of DIS and reflux symptoms. Twenty-three patients presented a regression of asthmatic symptoms with normalization of FEV1. Four patients reported a significant improvement of symptoms and their FEV1 was over 80%. CONCLUSION: GERD is a highly prevalent condition in asthma patients. Treatment with pantoprazole (80 mg/day) determines their improvement and complete regression.     

生长抑素联合泮托拉唑治疗上消化道出血患者的效果

目的:观察生长抑素联合泮托拉唑治疗上消化道出血患者的效果。方法:选取60例上消化道出血患者作为研究对象,按随机数字表法将其分为对照组与研究组各30例。对照组予以泮托拉唑治疗,研究组在对照组基础上联合生长抑素治疗,比较两组临床相关指标水平、临床疗效和不良反应发生率。结果:研究组止血时间短于对照组,出血量少于对照组,差异均有统计学意义(P<0.05);研究组治疗总有效率为96.67%(29/30),明显高于对照组的70.00%(21/30),差异有统计学意义(P<0.05);两组不良发应发生率比较,差异无统计学意义(P>0.05)。结论:生长抑素联合泮托拉唑治疗上消化道出血患者可提高治疗总有效率,缩短止血时间,以及减少出血量的效果优于单纯泮托拉唑治疗。